Please note that our online payment system is down due to maintenance and will be reopened by Tuesday 24 January.
Registration is still possible for those that choose to pay later.
We apologise for any inconvenience this may cause.
- Unleashing endogenous immunity
- Clinical studies of T cell-based immunotherapies
- Markers of effective immune responses
- Targeting the microenvironment
- Inducing immunity
The 2017 EMBL-Cancer Core Europe Conference on Cancer Immunotherapy will cover highly relevant sub-disciplines of cancer immunology with a special focus on personalised immunotherapy.
The European Molecular Biology Laboratory (EMBL) and Cancer Core Europe - a consortium of Europe's 6 leading Comprehensive Cancer Centers (Gustave Roussy Cancer Campus Grand Paris, France; Cambridge Cancer Centre, United Kingdom; Karolinska Institutet, Sweden; Netherlands Cancer Institute (NKI), Vall d’Hebron Institute of Oncology, Spain and the German Cancer Research Centre (DKFZ) with it's National Center for Tumour Diseases (NCT) Heidelberg) - are proud to join forces to host the first EMBL-Cancer Core Europe Conference on Cancer Immunotherapy.
Who should attend?
The conference will bring together international basic, translational and clinical scientists and physicians from academics to industry.
This conference is organised in cooperation with DKFZ and NCT Heidelberg.